Abstract:Marscha S Holleman, 1,2 Harm van Tinteren, 3 Harry JM Groen, 4 Maiwenn J Al, 1,2 Carin A Uyl-de Groot 1,2 1 Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands; 2 Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands; 3 Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands; 4 Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, an overall view for comparing efficacy and toxicity on a meta-level is lacking. This study compared efficacy and toxicity of first-line treatment with five different EGFR-TKIs by conducting a network meta-analysis (NMA). Methods: A systematic review was performed, aiming to find eligible literature. Data of PFS, overall survival (OS), objective response rate (ORR), and adverse events were extracted. An NMA based on Bayesian statistics was established to synthesize the efficacy and toxicity of all treatments. Results: Thirteen randomized controlled trials, including data from 3,539 patients with EGFR-mutated NSCLC, were analyzed. Rank probabilities showed that osimertinib had a potentially better efficacy in terms of PFS and OS compared to all other TKIs. For ORR, afatinib and osimertinib showed a trend of superiority compared to the other four TKIs. Furthermore, there was a high risk of diarrhea and rash for patients treated with afatinib or dacomitinib as well as a moderate risk for treatment with erlotinib, gefitinib, and osimertinib. Conclusion: Our study showed a favorable efficacy of osimertinib in terms of PFS and OS compared to all other EGFR-TKIs in patients with NSCLC harboring activating EGFR mutations. Furthermore, gefitinib, erlotinib, and osimertinib were associated with fewer toxicities compared to the other TKIs. Therefore, osimertinib is indicated as a preferable first-line TKI in patients with activating EGFR-mutated NSCLC. Keywords: EGFR-TKI, gefitinib, erlotinib, afatinib, osimertinib, network meta-analysis

Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression

Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib

Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Coexistence of Sensitive and Resistant Epidermal Growth Factor Receptor (EGFR) Mutations in Pretreatment Non-Small Cell Lung Cancer (NSCLC) Patients: First or Third Generation Tyrosine Kinase Inhibitors (Tkis)?

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Osimertinib or EGFR-TKIs/chemotherapy in Patients with EGFR-mutated Advanced Nonsmall Cell Lung Cancer

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib

Optimizing First-Line TKI Treatment Efficacy in PD-L1-positive EGFR-mutated NSCLC: the Impact of Antiangiogenic Agents